Pharma Mar SA · BME:PHM
Pharma Mar SA — Zeltia — CONCORD 2010
21 slides from Pharma Mar SA's conference presentation, Mar 4, 2010
Slide 1: CONCORD 2010: Presentation
Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview CONCORD 2010: Presentation 4 March 2010 1
Slide 2: Disclaimer
Disclaimer Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview “This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-
Slide 3: Corporate Overview
Zetia Corporate Overview
Slide 4: History of Delivering Commercial Success
History of Delivering Commercial Success Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Founded in Spain in 1939 and listed Founded: 1939 in 1963. Listed: 1963 Ticker: ZEL SM Holding company with core business in biotechnology. Ma
Slide 5: Strategy & Approach
oZettia Strategy & Approach
Slide 6: Adopting a Unique Approach to Creating Commercial Value
Adopting a Unique Approach to Creating Commercial Value Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview The Sea: – Great source of biological material for drug discovery and development – Zeltia’s library includes 85,000 marine sam
Slide 7: Our Human Resources commitments
Our Human Resources commitments Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Zeltia’s Total work force To hire Highly-qualified people (by gender aspects) – Over 72% of the Biotech’s employees are PhDs 52% 48% and graduates % of
Slide 8: Success Story: Yondelis
Success Story: Yondelis Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Our approach has proven successful: YONDELIS® New marine derived chemical entity with a novel Mechanism of Action EU Marketing Authorisation for 2 indications
Slide 9: Oncology: Yondelis & Pipeline
Oncology: Yondelis® & Pipeline
Slide 10: Pipeline Yondelis
Pipeline Yondelis® Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Soft Tissue Sarcoma (STS) – 2nd/3rd line Relapsed ovarian cancer (Yondelis+Doxil)- 2nd/3rd line Yondelis® STS with translocations-1st line 12.000 treated patients P
Slide 11: Strong Oncology Pipeline
Strong Oncology Pipeline Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Relapsed/refractory multiple myeloma Relapsed/refractory Aplidin® T-cell lymphoma 756 treated patients Mielofibrosis Aplidium albicans Combination studies Cer
Slide 12: Forthcoming pivotal trials: Aplidin
Forthcoming pivotal trials: Aplidin® Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview • Phase II/III pivotal trial in refractory Multiple Myeloma: 2Q010 − 3rd line, in combination with DEXAMETHASONE vs. DEXAMETHASONE − 250 patients
Slide 13: Yondelis: Commercially Driven Licensing Agreements
Yondelis®: Commercially Driven Licensing Agreements Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Yondelis® Disease Overview 2001: – Licensing agreement initiated with CENTOCOR ORTHO BIOTECH, subsidiary of Johnson & Johnson's 2009: – Licensing ag
Slide 14: Yondelis: Significant Market Potential Unlocked through Regional Specialists
Yondelis®: Significant Market Potential Unlocked through Regional Specialists Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Yondelis® Disease Overview Western Europe (88% of European market) Sales force: PharmaMar / Innovex (Quintiles) Scandinavi
Slide 15: Alzheimer's Disease and Other Dementias
Alzheimer’s Disease and Other Dementias
Slide 16: Exciting CNS Pipeline Candidates
Exciting CNS Pipeline Candidates Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Disease Overview REGULATORY PRECLINICAL DEVELOPMENT CLINICAL DEVELOPMENT TOXICOLOGY NYPTA® (NP-12) p.o. GSK-3 Inhibitor Alzheimer’s Disease NYPTA® (NP-12) p.o.
Slide 17: NYPTA: Transgenic Mice
NYPTA®: Transgenic Mice Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Oral chronicle treatment AMYLOID AMYLOIDpathology pathology TAU TAU phosphorylation phosphorylation with NYPTA®: – Significantly reduces the amyloide plaques –
Slide 18: Alzheimer's: High Sales Estimates for Treatment Capable of Retarding Neurodegenerative Process
Alzheimer’s: High Sales Estimates for Treatment Capable of Retarding Neurodegenerative Process Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Sales of Alzheimer's Drugs in 2008* Brand Company Generic Class Sales 2008 (m$) +/- (%)
Slide 19: Financial Overview
oZettia Financial Overview
Slide 20: Focussed on Developing a Strong R&D Programme
Focussed on Developing a Strong R&D Programme Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview R&D Expenditure – Year on Year Net Revenue by Segment – Year on Year (Euro ‘000) (Euro ‘000) 0 .0 0 11 7 34 00 ,5 .0 0 91 00 57 64 02 ,6
Slide 21: Sales in Biotechnology: national & international
Sales in Biotechnology: national & international Corporate Strategy & Oncology: Oncology: Alzheimer’s Financial Overview Approach Pipeline Yondelis® Disease Overview Oncología (Yondelis ®) Diagnostics Kits (CLART®) Sales (Euros) Sales in Spain 3500000 +51% 40.000.000 +58% 3000000 35.000.000 2500000